Product Details

CJC-1295 without DAC is a synthetic peptide derived from a modified sequence of Growth Hormone Releasing Factor (GRF), specifically MOD-GRF 1-29. It is structurally distinct from CJC-1295 with DAC due to the absence of the Drug Affinity Complex (DAC), which alters its stability and receptor interaction dynamics in research settings.

This peptide consists of a defined chain of amino acids and is primarily examined in laboratory environments for its interaction with signaling pathways associated with growth hormone regulation. Its structural properties allow for controlled investigation of peptide-receptor binding and signaling modulation.

CJC-1295 without DAC is supplied strictly for in vitro research purposes and is not intended for use in living systems.

Mechanism of Action

CJC-1295 without DAC is classified in biochemical research as a growth hormone-releasing factor (GHRF) analog, interacting with receptors associated with the growth hormone signaling axis.

At the molecular level, it is studied for its binding interaction with growth hormone-releasing hormone receptors (GHRH-R), which are involved in intracellular signaling cascades linked to cyclic adenosine monophosphate (cAMP) activation.

GHRH-R Binding→cAMP Activation→Signal Transductiontext{GHRH-R Binding} rightarrow text{cAMP Activation} rightarrow text{Signal Transduction}GHRH-R Binding→cAMP Activation→Signal Transduction

This interaction is examined in controlled systems to analyze downstream signaling events, including receptor activation patterns and peptide-mediated signaling dynamics. The absence of DAC is associated with shorter interaction duration in experimental models, enabling investigation of transient receptor activation and pulsatile signaling behavior.

Chemical Properties of  CJC-1295 without DAC 

Research Applications

GHRH Receptor Interaction Studies

CJC-1295 without DAC is utilized in experimental models to examine binding interactions with growth hormone-releasing hormone receptors. These studies focus on receptor affinity, activation profiles, and ligand-receptor specificity.

Intracellular Signaling Pathway Analysis

This peptide is applied in research investigating cAMP-mediated signaling cascades and downstream molecular events associated with receptor activation.

Pulsatile Signaling Investigation

Due to the absence of DAC, CJC-1295 without DAC is frequently used in studies analyzing transient receptor engagement and pulsatile signaling patterns within controlled environments.

Why Choose BehemothLabz to Buy CJC-1295 (No DAC) for Research

BehemothLabz provides research-grade CJC-1295 (No DAC) manufactured under controlled laboratory conditions with strict quality assurance protocols. Each batch undergoes analytical verification to ensure consistency in molecular composition and purity.

Comprehensive documentation, including laboratory testing reports and sourcing transparency, supports reproducibility in experimental settings. BehemothLabz maintains a compliance-focused approach, supplying compounds intended strictly for laboratory-based investigation and analytical research

Disclaimer

CJC-1295 (No DAC) is intended strictly for laboratory research and analytical purposes only. It is not intended for use in diagnostic procedures, therapeutic applications, or in vivo studies of any kind.

Any references to biochemical pathways, receptor interactions, or enzymatic processes are provided solely for informational and research-context purposes. This compound must be handled exclusively by qualified professionals in controlled laboratory environments in accordance with applicable regulations and safety guidelines.

Improper handling or use outside of controlled research settings is strictly prohibited.

References

• Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 91(3), 799–805. https://doi.org/10.1210/jc.2005-1536 
• Timms, M., Ganio, K., & Steel, R. (2019). A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS. Drug testing and analysis, 11(8), 1248–1257. https://doi.org/10.1002/dta.2599